600829 Stock Overview
Engages in the wholesale and retail of pharmaceutical products in China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
HPGC Renmintongtai Pharmaceutical Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.48 |
52 Week High | CN¥8.79 |
52 Week Low | CN¥4.96 |
Beta | 0.45 |
11 Month Change | 7.82% |
3 Month Change | 8.54% |
1 Year Change | -12.55% |
33 Year Change | 5.19% |
5 Year Change | -13.60% |
Change since IPO | 643.02% |
Recent News & Updates
Shareholder Returns
600829 | CN Healthcare | CN Market | |
---|---|---|---|
7D | 21.8% | 0.7% | 0.8% |
1Y | -12.6% | -34.8% | -20.8% |
Return vs Industry: 600829 exceeded the CN Healthcare industry which returned -34.8% over the past year.
Return vs Market: 600829 exceeded the CN Market which returned -20.8% over the past year.
Price Volatility
600829 volatility | |
---|---|
600829 Average Weekly Movement | 5.9% |
Healthcare Industry Average Movement | 5.1% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.8% |
10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 600829 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600829's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1950 | 2,960 | Weidong Zhu | www.hyrmtt.com.cn |
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese medicines, Chinese herbal medicine, antibiotics, biological products, and biochemical drugs, as well as medical equipment and health products. It also provides logistics services, including warehousing and distribution; and hospital services comprising medical treatment, prevention, health care, rehabilitation, blood purification, and renal disease treatment.
HPGC Renmintongtai Pharmaceutical Corporation Fundamentals Summary
600829 fundamental statistics | |
---|---|
Market cap | CN¥3.76b |
Earnings (TTM) | CN¥274.01m |
Revenue (TTM) | CN¥10.10b |
13.7x
P/E Ratio0.4x
P/S RatioIs 600829 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600829 income statement (TTM) | |
---|---|
Revenue | CN¥10.10b |
Cost of Revenue | CN¥9.16b |
Gross Profit | CN¥943.87m |
Other Expenses | CN¥669.86m |
Earnings | CN¥274.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.47 |
Gross Margin | 9.35% |
Net Profit Margin | 2.71% |
Debt/Equity Ratio | 36.8% |
How did 600829 perform over the long term?
See historical performance and comparison